CREATE, Monash Partner to Advance In Vivo CAR-T Platform
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...
LEXINGTON, Mass., July 6, 2026 Curis, Inc. announced an important enrollment milestone for its Phase 2 TakeAim CLL clinical...
LEXINGTON, Mass., June 26, 2026 Curis, Inc. announced continued progress in its Phase 2 TakeAim CLL clinical trial, confirming...
SHANGHAI, China, June 26, 2026 Everest Medicines announced a significant regulatory milestone after China’s National Medical Products Administration (NMPA)...
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...
